Harmonised patient safety across the EU — from the Council Recommendation to national reporting systems, cross-border adverse event management, and EU-wide safety indicators.
The EU Council Recommendation on Patient Safety (2009/C 151/01) established the framework for Member States to develop national patient safety programmes. While implementation varies, core principles are harmonised: adverse event reporting, healthcare-associated infection prevention, safe surgery protocols, and medication safety. The WHO Global Patient Safety Action Plan 2021–2030 provides the international reference framework adopted across EU Member States.
Harmonised identification protocols across EU healthcare systems. Two-identifier verification, electronic patient identification, and cross-border patient matching under the EHDS interoperability framework.
Standardised handover protocols (I-PASS, SBAR) endorsed across EU Member States. Multilingual communication challenges in cross-border healthcare and the role of structured clinical communication tools.
EU pharmacovigilance framework under Regulation (EU) 1235/2010. Cross-border medication reconciliation, LASA medication management, and the European Medicines Verification System (EMVS).
WHO Surgical Safety Checklist implementation across EU Member States. National adaptations, compliance monitoring, and integration with the EU Regulation on Clinical Trials (EU 536/2014).
ECDC-coordinated surveillance of healthcare-associated infections. EU antimicrobial resistance action plan, harmonised infection control standards, and cross-border outbreak management.
OECD Healthcare Quality Indicators, EU Patient Safety Culture surveys, and harmonised adverse event classification (WHO International Classification for Patient Safety) across Member States.
Each Member State operates its own adverse event reporting system (e.g., NRLS in UK, CIPM in France, CIRS in Germany). Understanding local requirements is essential for cross-border organisations.
The European Database on Medical Devices centralises vigilance reporting for medical device incidents across the EU under MDR/IVDR. Mandatory reporting timelines: serious incidents within 15 days, trends within 90 days.
The EU pharmacovigilance database managed by EMA. Mandatory reporting of suspected adverse drug reactions. Individual Case Safety Reports (ICSRs) within 15 days for serious reactions.
When adverse events involve cross-border healthcare (under Directive 2011/24/EU), coordination between national contact points, competent authorities, and the European Commission is required.
Clinical compliance across the EU integrates with a specialised ecosystem covering every dimension of healthcare regulation — from data protection and cybersecurity to sector-wide compliance and dedicated officer services.
Central hub for comprehensive healthcare regulatory compliance
Visit healthcarecompliance.pt →Data protection in clinical research and healthcare practice
Visit clinicaldataprotection.pt →Specialised cybersecurity for hospitals and healthcare organisations
Visit healthcybersecurity.pt →Clinical compliance platform for Portuguese healthcare organisations
Visit clinicalcompliance.pt →Need support implementing EU patient safety standards across multiple jurisdictions? Contact our team for expert guidance.